Gilead targets two million remdesivir courses by year-end
(Reuters) - Gilead Sciences Inc expects supply of its potential COVID-19 drug remdesivir to exceed two million courses by year-end, the company said on Monday, more than double its previous target of 1 million.
The company also said it planned to start trials of an easier-to-use inhaled version of the antiviral drug, currently administered only intravenously, by August.
Remdesivir is at the forefront in the fight against the virus after the drug helped shorten hospital recovery times in a clinical trial. But producing and supplying billions of doses remain major concerns as the fast-spreading respiratory illness overwhelms healthcare systems around the world.